Intellia Therapeutics, Inc. $NTLA Stock Holdings Lessened by Discovery Value Fund

Discovery Value Fund decreased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 57.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,976 shares of the company’s stock after selling 130,725 shares during the quarter. Intellia Therapeutics makes up 2.3% of Discovery Value Fund’s investment portfolio, making the stock its 2nd largest position. Discovery Value Fund’s holdings in Intellia Therapeutics were worth $881,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of NTLA. Comerica Bank increased its position in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the period. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics in the second quarter valued at about $26,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Intellia Therapeutics in the third quarter valued at about $30,000. Advisory Services Network LLC purchased a new position in shares of Intellia Therapeutics in the third quarter valued at about $33,000. Finally, Spire Wealth Management purchased a new position in shares of Intellia Therapeutics in the fourth quarter valued at about $37,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of analyst reports. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Canaccord Genuity Group reduced their price target on shares of Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. The Goldman Sachs Group boosted their price target on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research report on Tuesday, April 28th. JonesTrading upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Wednesday, March 4th. Finally, Chardan Capital boosted their price target on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $12.35 on Friday. Intellia Therapeutics, Inc. has a one year low of $7.95 and a one year high of $28.25. The company’s 50-day simple moving average is $13.62 and its 200 day simple moving average is $12.30. The firm has a market capitalization of $1.73 billion, a P/E ratio of -3.49 and a beta of 1.92.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The business had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter in the previous year, the firm posted ($1.10) earnings per share. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.